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Today, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are 
believed to have increased survival rate in patients affected by peritoneal carcinomatosis. However, 
cured patients and long-term survivors have ongoing health care problem after their treatment is 
successfully completed.  
Aim  
The aim of this study was to compare quality of life (QoL) of cancer survivors treated with 
cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) versus 
current oncological standard care. 
 Method  
Fifteen QLQ-C30 (QLQ-C30, a cancer specific instrument for measurement of QoL) primary 
research studies that relate to the QoL in CRS-HIPEC recipients and meet pre-set eligibility criteria 
were selected to conduct a systematic literature review. 
 Results  
The QoL was characterized by high scores at the baseline, a short-term decrease during1-3 month 
postoperatively. Thereafter, there was an increase in QoL during the subsequent 6-12 months 
followed by improvement in long-term survivors but there was a decrease in QoL as a result of 
recurrence. The QoL was similar when compared with the reference groups, but it was lower than in 
the general population. QoL after CRS and HIPEC can be equivalent to that of well-functioning, 
disease-free cancer patients. 
Conclusion 
QoL after CRS and HIPEC can be equivalent to that of well-functioning, disease-free cancer patients. 
Patients receiving CRS combined with HIPEC need continuum care assistance across hospital, home 
and other settings to cope with short-term and long-term effects of cancer diagnosis and therapy. 
Findings suggest a comprehensive approach of care that will consider delivery of adequate clinical 
information, individuals’ preferences, perceptions, and participation in decision-making. 
Keywords: Quality of life, QLQ-C30, Cytoreductive Surgery, Hyperthermic Intraperitoneal 
Chemotherapy. 
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Peritoneal carcinomatosis (PC) refers to the condition by which cancer cells from the secondary 
spread of intra-abdominal tumors such as colorectal cancer, disseminates into peritoneum. Tumor 
involvement in the peritoneum has previously been regarded as a terminal condition, which requires 
palliative surgery and chemotherapy. Advances in research has made changes in the different 
treatment approaches of PC from palliative to curative intent. Since cytoreductive surgery (CRS) has 
been combined with hyperthermic intraperitoneal chemotherapy (HIPEC), the survival period has 
increased ranging from six months to up to five years and even longer in selected patients (Alzahrani 
et al., 2016). 
In view of the significant extent of surgery and chemotherapy, this treatment approach remains an 
extensive and high-risk procedure in which many organs are removed, and a large area of normal 
anatomy is altered. The surgical procedure alone takes much longer, and it is more painful than other 
main surgeries performed on the abdominal cavity (Schmidt, Creutzenberg, Piso, Hobbhahn & 
Bucher, 2008). Subsequently, CRS-HIPEC recipients have postoperative complex health care 
problems that impair their quality of life (Zhu, Hanna, Boutros & Alexander, 2013; Passot et al., 
2014). Traditionally, health care professionals can support patients to improve the overall 
postoperative quality of life, but the resultant improvement of quality of life depends on the self-care 
ability of the individual patient (Shahsavari, Matory, Zare,Taleghani & Kaji, 2015).  
To move beyond the focus of morbidity and mortality and address the question to PC survivors about 
their experience, so far, only few nursing studies have been conducted to investigate the perspectives 
of patients undergoing CRS/HIPEC treatment. These studies indicate that nurses do not always pay 
attention to issues of care that are required by the patients’ condition. Ideally, patients need to be 
involved in the pathway of treatment, experience a decrease in symptoms associated with PC, and 
improve their ability to return to a normal level of functioning (Eriksson, Haglund, Leo Swenne & 
Arakelian, 2014; Leo Swenne, Jangland &Arakelian, 2017; Thaysen, Lomborg & Seibaek, 2019). 
However, there is a lack of comprehensive approach to understanding symptoms and their impact 
on recovery of patients with PC. This lack of knowledge contributes to poor symptoms management 
and poor quality of life (Francescutti et al., 2019). 
CRS-HIPEC survivors experience treatment as a turning point stained with worries about their future 
mixed with hope from uncertain cure. In a long recovery process, distress regarding the return of the 
disease, financial difficulties, changes in family role, uncertain follow-up care, and feelings of being 
forgotten by healthcare system remain a major concern (Eriksson et al., 2014; Leo Swenne et al., 
2017).  
This research was designated to evaluate the benefits of CRS plus HIPEC in comparison to current 
oncological care standard in an effort to decrease burdensome symptoms and improve quality of life 
of cancer survivors.  
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2 Background 
2.1 Pathophysiology of Peritoneal Carcinomatosis  
The peritoneum is the largest serous membrane with a surface area of approximately 1,8 m² which 
is almost the same size as the surface of the human skin. It is located in the abdominal cavity and 
continues into the pelvic cavity. The role of peritoneum is to facilitate the movement of visceral 
organs over each other, maintain equilibrium in the abdominal cavity, and provide defense 
mechanisms against intra-abdominal infections (Lemoine, Sugarbaker &Van der Speeten, 2016).  
Peritoneal carcinomatosis (PC) indicates tumor that spreads from internal organs to the peritoneum 
and structures of the abdominal cavity. It is a sign of cancer progression in advanced stage with a 
very poor diagnosis (Van Baal et al., 2017). 
Two pathways explain the pathogenesis of PC:  
1. Primary tumor of the peritoneum 
Primary PC develops directly from cells lining the peritoneum or abdominal cavity. It is a form of 
cancer that is rare, and accounts for 10% of all peritoneal carcinoma. The most reported cases have 
been found in women (Coccolini et al., 2013).  
2. Dissemination from the primary tumor 
Tumor cells detach from the primary tumor and gain access to the peritoneal cavity. Tumor 
dissemination into the peritoneal cavity could be triggered by spontaneous perforation of the primary 
cancer or dissection of lymph or blood vessels during surgery. Once the cancer cells are seeded in 
the peritoneal cavity, they can spread into different anatomical regions of the abdominal cavity 
(Kusamura et al., 2010). Several gastrointestinal and urogenital malignancies have the potential to 
disseminate and grow in the peritoneal cavity but other forms of distant tumor such breast cancer 
can disseminate into peritoneum (Brcher et al., 2012).  
Commonly, tumor nodules grow on the intestinal surface causing the progressive obstruction of the 
gastrointestinal function. Abdominal pain, nausea, and constipation associated with severe weight 
loss are more recurrent symptoms (Spratt, Edwards, Kubota et al. 1986). In some cases, bloating can 
be caused by a large amount of fluid accumulated in the abdomen as a result of malignant ascites. 
The patient may tolerate this situation until abdominal distension becomes intolerable. Death usually 
occurs as a result of complete bowel obstruction (Spratt, et al. 1986). 
2.2 Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal 
Chemotherapy (HIPEC) 
The first combination of surgery and heated chemotherapy to treat patients affected with peritoneal 
carcinomatosis started in the1980’s in USA (Spratt, Adcock, Muskovin, Sherrill, & McKeown, 
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1980). It became popular in the late eighties. Today, patients receiving cytoreductive surgery (CRS) 
and hyperthermic intraperitoneal chemotherapy (HIPEC) may live three to five years even longer 
(Alzahrani et al., 2016). 
The combination of CRS+HIPEC consists of first removing any visible cancer cells and then 
delivering heated chemotherapy directly into the abdominal cavity. The combination of heat and 
chemotherapy is believed to penetrate more deeply in cancer cells than the standard chemotherapy 
(Baker, Morzorati & Ellett, 2005). Depending on the extent of disease, the procedure may take more 
than 10 hours to be completed (Brcher et al., 2012). Traditionally, patients remain in the hospital 
longer than the median length of hospital stay after post-abdominal surgery (Dranichnikov, Graf & 
Cashin, 2020). 
Following the CRS+HIPEC treatment, the recovery time is associated with an increased risk of 
various complications and death (Martin et al., 2016). Within 30 days of the procedure, more than 
fifteen percent of patients may require readmission associated with digestive complications and 
postoperative infections though the incidence of readmission decreases over the time (Paredes, 
2019). The Foster et al. (2019) study was the first comparative analysis to reveal that CRS+HIPEC 
treatment is safe compared with similar high-risk oncologic procedures.  
2.3 Postoperative Recovery and Quality of Life  
The World Health Organization (WHO, 1948) defined health as “A state of complete physical, 
mental and social well-being, and not merely the absence of disease or infirmity”. This definition 
was the first to establish the dimensions of health in connection with illness and disease. However, 
health connection to the Quality of Life (QoL) concept was introduced later in medical literature. 
The first instrument designed as (QoL) measure was introduced as Spitzer’s QL-index (Spitzer et 
al., 1981). The concept reflected the subjective patient-reported effect of illness and treatment on 
physical, psychological and social aspects of life that appear to be influenced by human experience, 
spiritual, cultural and environmental dimensions (Fayers & Machin, 2016, p 4). 
Postoperative assessment of quality of life has grown as a standard tool in clinical studies, anywhere 
therapeutic benefits need to be evaluated. QoL indicates the set of outcomes that contribute to a 
patient’s well-being or recovery, in which case the effects of illness and treatment on a patient’s 
recovery profile are evaluated. It is important to realize that preoperative QoL partially predicts how 
well the recovery process may improve, and positive changes in QoL scores during treatment have 
prognostic values making it believable of its curative effect (Fayers & Machin, 2016, p. 16).  
Postoperative recovery is a process of returning to normal activities, which were impaired after the 
operation, by regaining control over physical, emotional, social and habitual functions. The goal is 
to return to the preoperative baseline level of independence in activities of daily living. Three phases 
have been identified in the postoperative recovery: early, intermediate and late recovery. The early 
phase begins after discontinuation of anesthesia with a return to consciousness and recovery of vital 
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reflexes mainly airway and motor activity. The stabilization of vital functions occurs in the 
intermediate phase until readiness to be discharged from care. The late phase is a return to 
preoperative health standards after discharge from the hospital (Allvin, Berg, Idvall & Nilsson, 
2007).  
Similar to postoperative recovery, QoL has multiple dimensions of which some are found to overlap 
with others. In fact, recovery from illness provides better quality of life scores (Berg, Kjellgren, 
Unosson & Arestedt, 2012). Neville et al. (2014) identified three fundamental dimensions namely 
physiological, symptomatic and functional dimension. The physiological dimension refers to a return 
to control over body function and regain of physical strength. The symptomatic dimension indicates 
a decrease or an increase in symptomatology such as from pain, fatigue, nausea/vomiting, and 
anxiety/depression while the functional dimension covers mobilization and ability to perform 
activity of daily living.  
In general, postoperative assessment of QoL contains seven dimensions or domains: physical, role, 
emotional (including anxiety and depression), cognitive, social, symptoms and global health (Fayers 
& Machin, 2016).  Pain, muscle weakness, fatigue, infections, anxiety and postoperative 
complications have been all reported as predictors of postoperative recovery that affect the QoL of 
CRS-HIPEC recipients (Martin et al., 2016).  
A large number of instruments are being used to assess QoL. Some instruments are intended for 
general use irrespective of the illness or condition of the patient. These are non-disease-specific 
instruments that may even be applicable to healthy people hence used in population surveys. The 
SF-36 is an example of an instrument of general use. Other instruments are condition- or disease-
specific such as in research and treatment of cancer (Fayers & Machin, 2016). Only the cancer-
specific instrument will be considered in this study. Considering homogeneity of data collected for 
the purpose of this review, the range of instruments has been reduced to only a QLQ-C30 (Quality 
of Life Questionnaire-Core 30) cancer specific instrument.  
The QLQ-C30 questionnaire was designed for assessing health related quality of life of cancer 
patients. It is the product of more than a decade of research run by the European Organization for 
Research and Treatment of Cancer (EORTC). The QLQ-C30 contains 30 -items questionnaire and 
incorporates five functional scales (physical, role, cognitive, emotional and social), three symptom 
scales (fatigue, pain, and nausea/vomiting), additional six single items common for cancer patients 
(dyspnea, loss of appetite, insomnia, constipation, diarrhea and perceived financial difficulties 
associated with disease), and one overall quality of life scale (Aaronson et al., 1993). 
 This disease-specific instrument has been used in a wide range of cancer patients since 1993 (see 
Appendix E) as it has been easily proved to detect differences between patients, treatment effects 




2.4 Nursing Theory Relevant to Enhance Quality of Life   
This section introduces the Orem’s Self-Care Deficit Theory. It will include functional scales, and 
symptoms experienced by CRS-HIPEC patients as components of self-care that influence quality of 
life.  
The concept of Self-Care was first introduced and later Self-Care Deficit by Dorothea Orem. The 
primary source of Orem’s ideas was her clinical experience in nursing and reflection on nursing 
situations. The self-care theory is a combination of three theories: theory of self-care, theory of self-
care deficit and theory of nursing system (Masters, 2015, p.156). This theory highlights the 
importance of nurse’s support to patients in taking joint responsibility for their health (Alligood, 
2014, p.244) 
The literature outlines a range of factors to be taken into account in order to enhance self-care 
activities in cancer survivors. These factors include patient experience, patient-centered care, patient 
independence, and symptom detection or monitoring. 
Patient’s experience may reveal self-care needs that should be addressed by healthcare team to 
provide appropriate comprehensive care (Francescutti et al., 2019). The CRS-HIPEC treatment 
pathway can be perceived as great-test of stamina or a matter of personal preference to allow patients 
being fully involved. Since patients perceive this treatment as the only way to survive, they feel 
under emotional and cognitive pressure while monitoring their symptoms continuously (Dong et al., 
2016; Thaysen, Lomborg & Seibaek, 2019). 
In the context of cancer survivors, patient-centered care depicts a shift from paternalistic, provider-
driven, disease-focused approaches in an effort to support patients to make choices allowing them to 
manage their self-care needs. A patient-centered care approach is relevant to make a healthcare plan 
in partnership with patient, family members and a healthcare team. Research evidence supported 
person-centered web-based intervention to facilitate self-care in patients with cancer undergoing 
chemotherapy, particularly in symptom monitoring via mobile phones (Young et al., 2020).  
The patients’ awareness of terminal illness stressed at the time of the initial diagnosis or fear of the 
return of illness, is the beginning of the most physical and emotional difficulties. The use of symptom 
diary has improved patient self-care management and enabled discussion around treatment-related 
symptoms with healthcare team. A qualitative survey assessed patients’ use of the diary during 
chemotherapy treatment. Symptom diary was perceived as a tool for symptom detection, symptom 
relief as well as symptom management. Diary reports improved communication and discussion 
between patients and healthcare professionals (Coolbrandt et al., 2017).  
Quality of life is not only an important concern for individual cancer patients, but also a matter of 
importance for nursing care in which QoL assessment is imperative in terms of signposting the need 
for self-care (Bahrami & Arbon, 2011). 
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Nausea and vomiting are the most common side effects induced by chemotherapy in cancer patients 
subsequently, appetite loss, muscle weakness and fatigue may be increased (Richardson, 1991). 
Beside nausea and vomiting, other symptoms reputed to be disruptive particularly in the first three-
month period after CRS-HIPEC treatments include insomnia, pain, diarrhea and constipation. 
Reduced symptoms can be attained between three-six months after treatment (Piso et al., 2009).  
It is important to realize that the above-mentioned symptoms have been recognized since decades to 
interfere with self-care activities. Subsequently, self-care may be viewed in relation to dependence 
and interdependence care whereby lay people function on their own behalf to reduce postoperative 
symptoms with the assistance of the health care system. The blueprint of nursing care is to help 
patients meeting their therapeutic self-care demands (Richardson, 1991). 
In Sweden, the first national comprehensive readmission study for adverse events within the field of 
CRS and HIPEC, reported 25% of patients requiring intervention within 6 months (Dranichnikov et 
al, 2020). Evidence that there are limitations in the patient’s ability to perform self-care leads to the 
diagnosis of the self-care deficit. In fact, the notion of self-care deficit specifies when nursing care 
is required for the patient to meet self-care requisites. In this situation, the patient is more dependent 
on the nursing care system for current or future demands (Alligood, 2014, p.244). 
Deficits in self-care may result from lack of knowledge about the situation, incompetence in 
performing self-care activities, or malfunctioning of the person in a physical, role, emotional or 
social aspect due to illness (Alligood, 2014, p.244). Little is known about what self-care actions to 
cope with the side effects of cancer treatment. Few reports on self-care behavior of cancer patients 
undergoing chemotherapy have shown that cancer patients lack necessary information promoting 
self-care (Thaysen et al., 2019). 
Being diagnosed with PC and undergoing CRS-HIPEC treatment is a highly personalized experience 
known with potential risk to disrupt physical, emotional, psychological, spiritual, and social 
wellbeing of individuals and families (Francescutti et al., 2019). The nursing literature reports that 
loss of control in cancer survivors over their lives indicates a shift from independence to dependence 
on family, friends, or healthcare professionals for physical, emotional, or financial support. As the 
future turns unpredictable, self-care performance may become compromised (Kenten et al., 2019). 
To improve self-care, patients’ experience can assist nurses to determine what kind of care should 
be addressed in a given situation, but the end point is helping individuals maintain their autonomy 
(Francescutti et al., 2019). Orem’s self-care deficit theory reaffirms maintaining independence over 
one’s own self-care is the best way to promote recovery (Banfield, 2011).  
3 Research Problem 
Today, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may 
increase survival rate in patients affected by peritoneal carcinomatosis. Combined CRS-HIPEC 
treatment is associated with good quality of life though it remains in long-term survivors lower than 
in the general population. Both cured patients and long-term survivors have ongoing health care 
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problem after their treatment is completed (Glockzin, Schlitt & Piso, 2009; Piso et al., 2009). 
Concerns about CRS and HIPEC benefits remain (Gurusamy et al., 2020). 
The CRS-HIPEC treatment option has been perceived as a unique and complex pathway from 
diagnosis, treatment and discharge to local hospital, rehabilitation or home. Patients and relatives 
experienced challenges in term of their involvement in decision making as well as expressing their 
preferences (Thaysen et al., 2019). In few studies, survivors expressed uncertainties deriving from 
insufficient information with respect to symptom burden over time, lack of follow-up, and blurred 
rehabilitation plan (Leo Swenne, Cederholm, Gustafsson &Arakelian, 2015; Thaysen et al., 2019). 
Francescutti et al. (2019). It is imperative to notice the knowledge gap about the severity of side the 
treatment side effects in most candidates who made informed decisions about pursuing the CRS-
HIPEC procedure.  
Symptom management is the core of nursing work in improving quality of life of individuals 
undergoing cancer treatment. Nursing care encompasses strategies to prevent, delay, eradicate or 
minimize the symptom experience (Mathew, Doorenbos & Vincent, 2020).  Although CRS-HIPEC 
intervention has been performed for decades, the symptom line experienced that disrupt physical, 
mental, social, and spiritual functioning over time is less known (Research Agenda of the Oncology 
Nursing Society, 2019). Lack of knowledge on the QoL direction over time of patients who had 
undergone CRS-HIPEC treatment contributes further to poor symptom management and poor quality 
of life (Francescutti et al., 2019). 
Previous literature reviews addressing the quality of life in CRS-HIPEC patients have collected data 
from mixed instruments some of which intended for general use (Zhu, Hanna, Boutros & Alexander, 
2013; Shan et al., 2014). However, there is no preliminary review based on a cancer-specific tool to 
date. Nevertheless, little is known from primary sources about what quality of life dimension better 
improves or worsens postoperatively after CRS-HIPEC intervention. To get insight of QoL pattern, 
it was quite reasonable to compare CRS-HIPEC treatment with other oncological standard care for 
the awareness of human response to care delivered. QLQ-C30, a cancer specific instrument was used 
over the time to collect data from CRS-HIPEC subjects, and compare them with groups of cancer 
survivors, and the general population. 
4 Aim and Research Question 
The aim of the present review was to compare quality of life (QoL) of cancer survivors treated with 
cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) versus 
current oncological standard care 
The use of the acronym PICO (Population, Intervention, Comparison, Outcome) developed for by 
Bettany-Saltkov& McShery (2016) to investigate the aim of this review led to the following question: 
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In cancer survivors (P), does the use of HIPEC with CRS (I) versus current oncological standard 
care (C), provide better QoL outcome (measured by QLQ-C30 scale) (O)? 
Current oncological standard care includes any of the following treatments or combinations: surgery, 
systemic chemotherapy, or radiotherapy. 
5 Methods of the Review 
5.1 Study Design  
This study is a systematic review of primary studies. All available original clinical studies with or 
without a comparator group, that fit the pre-specified inclusion criteria, were identified, evaluated 
and interpreted (Snyder, 2019).  
5.2 Data Collection 
An electronic search was conducted using studies indexed in CINAHL, PubMed, Web of Science 
and Google scholar databases. CINAHL is the leading database for nurses and allied literature. While 
PubMed is wider than CINAHL comprising literature from medicine, nursing and other health 
professions, Web of Science is a multidisciplinary database covering medicine and sciences which 
are not directly connected to nursing or medicine (Cullum, Ciliska, Haynes & Marks, 2008). Original 
studies were more valuable to increase the quality of evidence than the secondary sources which 
were used to provide insights into the gap in the previous studies (Bettany-Saltikov & Mcsherry, 
2016). The search involved four key phrases generated from the research question: Quality of life, 
QLQ-C30, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy. 
Boolean operator AND was used to combine search terms into a search statement to include all terms 
in each record retrieved. Abstracts were checked if they were directly based on QoL after CRS and 
HIPEC. Finally, 15 articles were selected after being assessed for their quality according to Caldwell 
et al. (2011). In the primary search seven articles were selected, two additional articles were found 
on a secondary search and six in free text search (see Appendix A).  
5.3 Inclusion/Exclusion Criteria 
Participants in the included surveys were individuals who received CRS-HIPEC treatment and 
cancer survivors who underwent treatment with standard care regardless of their disease site in both 
adult males and females. The author of this study used a QLQ-C30 tool irrespective of their primary 
cancer site (see Appendix C). There was no limitation regarding the year of publication. English and 
French languages were considered. 
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Fifteen original articles published between 2005 and 2018 with their abstracts were selected of which 
one written in French and fourteen in English (fig.1). Peer reviews were verified by Ulrichweb tool, 
searched online articles from Gothenburg University library and checked for their authors’ 
credentials and affiliation to higher education (Willman, Stoltz & Bahtsevani, 2011). The level of 
evidence below 25 scores indicating low quality was an exclusion factor (Caldwell et al., 2011) as 
well as QoL assessed by external QLQ-C30 tools, since the latter are not specific for cancer. 
 
Fig.1: Flowchart of the review 
5.4 Quality Assessment of QLQ-C30 Research Articles 
The quality assessment of evidence was based on Caldwell et al. (2011) framework. The assessment 
focused on research design, sampling process, research method, analysis and result (Appendix B). 
The assessment deals with 18 questions where each question can be answered to provide a holistic 
assessment with the highest score set to 36. The lowest score of none was given to the question that 
was not answered at all while a partly or answered question was scoring respectively 1 or 2. In this 
study, the limit score to exclude a study was set to be lower than 60% (scores lower than 22/36) of 
the total scores. All studies within the scores between 30 and 34 which was the highest possible value 
were selected (see Appendix C). 
Articles identified through 
database searching
(296 records) Additional articles identified through hand 








Update search January 2021 Full text articles assessed for eligibility Full-text articles excluded (n=9)
(n=24) with reasons:
Reviews (n=4)





5.5 Data Analysis 
According to Bettany-Saltikov and Mcsherry (2016) model, three steps of analysis were considered: 
1. Articles were selected based first on their titles and abstracts which was followed by reading 
full papers several times and summarized to be familiar with its content, 
2. Quality assessment of selected papers was carried out by using a specific framework designed 
by Caldwell et al. (2011) 
3. Extracting data from selected articles. The comparison of combined data enabled the author 
to construct QoL in CRS-HIPEC recipients. 
The method involved grouping all items together into two separate groups namely a Baseline group, 
and a Control /general population group. Of the 15 reviewed articles, each paper was analyzed, and 
items extracted, and scores compared according to QLQ-C30 manual (Aaronson et al., 1993). The 
score is basically linearly transformed into 0-100 points. A higher functioning scale and global health 
status score represent better function and a better good health status. The higher the symptom scale 
and specific item score, the more severe are symptoms or problems (Fayers &Machin, 2016). The 
mean or median scores from the items of interest were compared before and after CRS-HIPEC 
treatment. 
6 Ethical Considerations 
All articles were checked for the ethics board approval prior to publication (Stryhn, 2007). In 
compliance with ethical standards for nursing research, data fabrication; falsification or data 
misrepresentation in reporting findings from quality assessment of articles were avoided (Houser, 
2008). To achieve good quality of evidence, the results are presented objectively regardless of 
whether they were negative or positive (Polit & Beck, 2018).  
 
CRS+HIPEC treatment has been reported to improve the survival and quality of life in patients with 
peritoneal carcinomatosis but concerns about its safety remain. Currently, the question under 
investigation is whether CRS plus HIPEC intervention can provide better outcomes than current 
standard oncologic management (Gurusamy et al., 2020; Auer et al., 2020). 
 
CRS+HIPEC therapy represents a terminal treatment where patients have not many other choices 
since definitive cure is unlikely (Nacoti et al., 2014). However, individuals affected with peritoneal 
metastasis do not have the same chance in terms of accessing treatment because of the high cost of 
the procedure. People who can afford to cater for the cost, economical support will be anyhow 
required during a recovery period in which return to work may be difficult (Gurusamy et al., 2020). 
 
It is worth noting that patients undergoing CRS-HIPEC therapy are faced with ethical and social 
issues. According to World Medical Association (2018), privacy and confidentiality, social 
vulnerability, health insurance discrimination, and employment discrimination may occur. 
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Confidentiality deals with the disclosure of information obtained during the course of patient care. 
In essence, such information shouldn’t be disclosed without the permission of the individual 
concerned (World Medical Association, 2018).  
 
Before the procedure, patients should be informed not only about its benefits but also the gravity of 
the risks involved, including postoperative quality of life (Nacoti, et al., 2017). However, this is not 
always the case. Since patients perceive this treatment as the only way to survive, concerns have 
been raised about treatment decisions that were taken solely by professionals based on physical state 
and the spread of the disease (Thaysen et al., 2019). 
 
7 Results 
7.1 Study Characteristics 
After a careful systematic selection, 15 studies with a total of 678 patients were included for review 
(Appendix D). Eight studies were meant to compare the QoL of patients after CRS-HIPEC treatment 
with the control or reference groups: the general population (Schmidt, Dahlke, Klempnauer, Schlitt 
& Piso, 2005), disease free cancer patients who were not on active treatment (Tan et al., 2013), 
postoperative complication after CRS-HIPEC (Hamilton, Taylor, Cannell, McCart & Govindarajan, 
2016), secondary CRS-HIPEC treatment (Zeng et al., 2017), and cancer survivors received standard 
care (Zenasni et al., 2009; Chia et al., 2014; Liu et al., 2016; Düzgün, Sarıcı & Gökçay, 2018). The 
comparison covers a 6-48 months’ period.  
The QoL of the seven remaining studies was assessed before and after CRS-HIPEC treatment on 
different periods of time. The follow-up period spanned from 1to 48 months. The key element in 
these studies was to compare the QoL at the baseline with a recovery or a recurrent period.  
The results of this systematic review are presented in two categories that emerged from the analysis: 
baseline group and control/general population group. The QoL scores of each group are arranged 
in three subcategories: functional scale, symptoms and global health status. 
7.2 The QLQ-C30 in the Baseline Group  
The baseline group was characterized by a high functional scale, a high global health scale, and a 
lower symptom scale in all studies. Financial difficulties were not mentioned as a problem before 
operation. However, emotional scores were lower meaning difficulties in emotional functioning 
(Jess, Iversen, Nielsen, Hansen, Laurberg & Rasmussen, 2008; Alves, Mohamed, Yadegarfar, 
Youssef & Moran, 2010; Stearns et al., 2018). Symptoms of nausea-vomiting, pain, insomnia, 
appetite loss, and constipation were mentioned in six studies though less recurring before treatment 
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(Jess et al., 2008; Alves et al.,2010; Tsilimparis et al., 2013; Albertsmeier, Hauer, Niess, Werner, 
Graeb & Angele, 2014; Chia, Tan, Lim, Soo & Teo, 2016; Stearns et al., 2018). (Table.1). 
Except the emotional function, the functional scale was impaired in all baseline group studies in a 
period 1-3 months postoperatively but later improved to the baseline level after 6- 24 months. Five 
studies underscored physical and cognitive impairment in the first six-month functional recovery 
period (Jess et al., 2008; Lim et al., 2010; Alves et al., 2010 Tsilimparis et al., 2013). The 
improvement of functional scores has been observed in long-term survivors who lived more than 7 
years later after treatment (Stearns et al., 2018). 
The emotional function was the unique variable which improved above the baseline as early as three 
months postoperatively (Jess et al., 2008; Alves et al., 2010; Tsilimparis et al., 2013). However, a 
slow recovery was indicated in cognitive functioning that did not return to baseline until 24 months 
or later after treatment (Jess et al., 2008; Tsilimparis et al., 2013; Stearns et al., 2018). Only one 
study reported a lack of significant alteration in cognition (Albertsmeier et al., 2014). 
High levels of symptoms representing worsening or problems were not reported in all baseline 
groups before CRS+HIPEC treatment. However, symptoms increased for a period of one to three 
months after surgery. Improvement started to appear at 6-12 months. Appetite loss, constipation, and 
insomnia returned to baseline between 12-24 months after surgery (Jess et al., 2008; Alves et al., 
2010; Tan, Lim, Soo & Teo, 2016). On the contrary, pain, fatigue, dyspnea, and diarrhea did not 
return to preoperative values within the same period (Jess et al., 2008; Lim et al., 2010; Tsilimparis 
et al., 2013). 
Financial difficulties increased during the first 12 months after surgery (Jess et al., 2008; Lim et al., 
2010; Albertsmeier et al., 2014). They improved thereafter, but increased again after 2 years (Jess et 
al., 2008; Tsilimparis et al., 2013) 
The global health status returned to baseline after 12- 24 months after surgery (Jess et al., 2008; 
Alves et al., 2010; Tsilimparis et al., 2013; Albertsmeier et al., 2014). Only one study showed a 
return of global health status above the baseline i.e., improvement (Albertsmeier et al., 2014). Short- 
term global health status was impaired in all baseline studies. Nevertheless, the global health status 
was improved in long-term survivors (Jess et al., 2008; Lim et al., 2010; Alves et al., 2010; 
Tsilimparis et al., 2013; Albertsmeier et al., 2014).  
The table below deals with studies in which QoL was assessed both before and after CRS+HIPEC 
treatment. Data collected before treatment was used as baseline to follow recovery improvement 




Table 1. QLQ-C30 Baseline Studies  
 
(Jess et al., 2008 ; Lim et al., 2010 ; Alves et al., 2010 ; Tsilimparis et al., 2013 ; Albertsmeier et 
al., 2014 ; Chia et al., 2016 ; Stearns et al., 2018). 
7.3 The QLQ-C30 in Control/General Population Group  
At 6-12 months’ follow-up, the score of functional scale was similar between patients receiving 
CRS-HIPEC treatment and oncology patients who received standard care (Zenasni et al., 2009; Tan 
et al., 2013; Chia et al., 2014; Liu et al., 2016; Düzgün et al., 2018). Functional scores improved in 
patient who received a second CRS-HIPEC treatment (Zeng et al., 2017). 
Three studies reported similarities in symptom scores in CRS-HIPEC groups compared to the control 
groups (Zenasni et al., 2009; Tan et al., 2013; Chia et al., 2014) though fatigue, nausea/vomiting, 
insomnia, pain, and diarrhea have all been reported to be more recurrent in CRS-HIPEC patients in 
a period of 6-48 months but without significant differences (Schmidt, Dahlke, Klempnauer, Schlitt 
& Piso, 2005; Hamilton, Taylor, Cannell, McCart & Govindarajan, 2016; Liu et al., 2016). All 
Results  of QLQ-C30 Studies Evaluation QoL  after CRS+HIPEC
Baseline 1 month 3 months 6 months 9 months 12 months 18 months 24 months 36 months ≥ 4 years
Physical ↑,↑,↑, ↑, ↑, ↑, ↑ ↓,↓,↓ ↓, ↓,↓,↓,↓ ↓,↓,↓,↓,↓ ↓,↑ B,B,↓,↓ ↑,↑ ↓,↓,↑ ↑,B B
Role ↑,↑, ↑, ↑, ↑, ↑, ↑ ↓,↓,↓ ↓,↓,↓,↓,↓ ↑,↓,↓,↓,↓ B,↑ ↓,↑,↓,↓ ↑,↑ ↑,↓,↑ ↓,↑ ↑
Emotional ↓,↑, ↓,↑, ↑, ↓,↑ ↓,↓,↓ ↑,↓,↑,↓,↑ ↑,↓,↑,↓,↑ ↑,↑ ↑,↑,↓,↑ ↑,↑ ↑,↑,↑ ↑,↑ ↑
Functional 
Scale Cognitive ↑,↑, ↓,↑, ↑, ↑, ↑ ↓,↓,↓ ↓,↓,↓,↓,↓ ↓,↓,↓,↓,↓ ↓,↓ ↓,↑,↓,↓ ↑,↑ ↓,↓,↓ ↓,↑ ↑
Social ↑,↑,↑,↑, ↑, ↑, ↑ ↓,↓,↓ ↓,↓,↓,↓,↓ ↑,↑,↓,↓,↑ ↓,↑ ↓,↑↓,↑ ↑,↑ ↓,↓,↑ B,↑ ↑
Fatigue ↓,↓,↓,↓,↓,↓,↓ ↑,↑,↑ ↑,↑,↑,↑,↑ ↑,↑,↓,↑,↓ ↓,↓ ↑,↓,↑,↑,↓ ↓,↓ ↑,↑,↓ ↑,↓ ↓
Nausea/ ↓,↑,↓,↓,↓,↓,↓ ↑,↑,↑ ↑,↓,↓,↑,↑ ↑,↑,B,↑,↑ ↓,B ↓,↓,↑,↑ ↓,↑ B,↑,↑ ↓,↓ ↓
Vomiting
Pain ↓,↓,↓,↓,↓,↑,↓ ↑,↑,↑ ↑,↑,↓,↑,↓ ↑,↑,↓,↑,↓ ↓,↓ ↑,↓,↑,↓ ↓,↓ ↑,↑,↓ ↓,↓ ↓
Dyspnea ↑,↓,↓,↓,↓,↓, ↑,↑,↑ ↓,↑,↑,↑ ↑,↑,↑,↑ ↓ ↑,↑,↑ ↓ ↑,↑ ↓
Insomnia ↑,↓,↓,↓,↓,↓,↓, ↑,↑,↑ ↓,↑,↓,↑,↓ ↓,↓,↓,↑,↑ ↑,↓ ↓,↓,B,↓ B,↓ ↓,↑,↓ ↑,↓ ↓
Symptoms
Appetite loss ↑,↓,↑,↓,↓,↓,↓ ↑,↑,↑ ↓,↑,↓,↑,↓ ↓,↑,↓,B,↓ ↓,↓ ↑,↓,↑,↓ ↓ ↓,↑,↓ ↑,↓ ↓
Constipation ↓,↑,↑,↓,↓,↓,↓ ↓,↓,↑ ↑,↑,↓,↓,↓ ↓,↓,↓,↓,↓ ↓,↓ ↑,↓,↓,↓ ↑,↓ ↓,↓,↓ ↓,↓ ↓
Diarrhea ↓,↓,↓,↓,↓,↓,↓ ↑,↓,↑ ↑,↑,↑,↑,↑ ↑,↑,↑,↑,↑ ↑,↓ ↓,↑,↑,↑ ↓,↓ B,↑,↑ ↓,↑ ↓
Financial ↓,↓,↓,↓,↓,↓,↓
Difficulties ↑,↑ ↑,↑,↑,↑ ↓,↑,↑,↑ ↑,↓ ↑,↑ ↑,↓ ↑,↑,↓ ↑,↓ ↓
Short-term
Global
Health Long-term ↓,↓,↓ ↓, ↓,B,↓,↓ ↓, ↓,↑,↓,↑ ↑,↑ ↑,↑,↑, ↓,↑ ↑,↑ ↓,↑,↑ ↑,↑ ↑
Baseline B B
Note: 
Decrease below baseline ↓
Increase above baseline ↑
Baseline group
17 
symptom scores were high before the second CRS-HIPEC intervention. They decreased significantly 
after intervention thereby showing the effect of the secondary CRS-HIPEC to improve quality of life 
(Zeng et al., 2017).  
In the reference groups (Zenasni et al., 2009; Tan et al., 2013; Chia et al., 2014; Hamilton et al., 
2016; Liu et al., 2016; Düzgün, Sarıcı & Gökçay, 2018) more than 70 % of patients did not report 
financial difficulties but they had more financial problems compared with the reference population 
norms in a period of 6-60 months (Stearns et al., 2018). 
The global health status improved significantly in patients who underwent the second CRS-HIPEC 
treatment (Zeng et al., 2017). It was low in long-term survivors compared to the general population 
norms (Schmidt et al., 2005) though it was without a significant difference between CRS-HIPEC 
recipients and patients undergoing classic surgical intervention, disease-free cancer patients or 
patients operated without HIPEC. Six months after surgery, the QLQ-C30 instrument could not 
detect any difference concerning the QoL between patients undergoing CRS-HIPEC treatment and 
patients undergoing classical surgery (Zenasni et al., 2009; Tan et al., 2013; Liu et al., 2016; Düzgün, 
Sarıcı & Gökçay, 2018). In addition, the QoL scores were similar after six months between patients 
who had undergone CRS-HIPEC treatment with and without complications (Hamilton et al., 2016). 
8 Discussion 
8.1 Methodological Considerations 
This paper is a review of primary scientific articles that includes 15 articles. The use of several 
databases was recommended to get the research question answered. The author identified a research 
problem within a topic of nursing interest regarding postoperative quality of life. To date, this is the 
first study to review QLQ-C30 studies linking data generated from baseline and from control groups 
or the general population after CRS+HIPEC. 
 
 The purpose of the research was to make contribution in finding a solution to the problem by 
generating relevant evidence. The research aim was used as a guide to set a limit to the type of data 
to collect and determine patient’ characteristics. Given various phases of recovery experienced by 
cancer survivors, evaluation of QoL was best investigated in longer follow-up period studies, and it 




Only primary sources were considered to increase evidence-based materials. One article written in 
French was ordered via the library as it only had the abstract available online. Of the total sample, 
80 % of selected articles were not older than 10 years. Nine studies were undertaken in Europe, five 
in Asia and one in Canada. Studies covering other continents were not available. At the moment, 
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there is limited data describing the QoL after CRS-HIPEC assessed by the QLQ-C30 instrument. 
Only 15 articles were found with unplanned exclusion of evidence-based nursing material, as they 
were not available at the time of data collection. Of the 15 articles that were selected, none was found 
in CINAHL database (Appendix A). 
 
The primary approach was to use as much as data from a prospectively designed study in which a 
pre-surgery assessment of QoL was assessed as the baseline, followed by postoperative assessments 
at different periods of time trends and compared to baseline scores (Zhu et al., 2013). However, the 
advantage of using control studies could not be neglected in terms of stipulating external factors that 
may affect the QoL after CRS-HIPEC treatment. A diversity of included studies from different 
geographic areas may be the main limitation of this literature review.  
Patients experience CRS+HIPEC treatment as a turning point generating uncertainties as well as 
barriers to meeting self-care requisites (Eriksson, Haglund, Leo Swenne &Arakelian, 2014). The 
oncology nursing practice is driven by a number of theories and conceptual models that provide 
frameworks essential for a holistic care where a collaboration with the patient and her /his family is 
necessary in all aspects of care (Payne, 2012, p.48). The underlying theory guiding this work 
displayed self-care as a tool to improve quality of life not only in the immediate postoperative 
recovery after discharge from the hospital but also throughout a long-term follow-up. 
The credibility of this study relies on the compatibility of the findings with both in the baseline group 
and the control or reference group besides the compliance with ethical standards implemented by 
evaluating the quality of articles relevant to the aim before selection (Polit & Beck 2018). To ensure 
validity, the author collaborated with peer debriefs through discussions (P.B., J.H., B.L., and B.S) 
re-analysis of raw materials and verification of the link between the purpose of this study and its 
results (DePoy & Gitlin, 1999). The selection of the scientific articles was not limited geographically, 
or any particular primary diagnosis related to the peritoneal carcinomatosis, hence excluding 
potential sources of bias and overviewing the results in a broad way. To minimize the risk of bias, 
all primary research papers have been included in this study (Bettany-Saltikov & Mcsherry, 2016).    
 
The main limitation of this study was inclusion of QLQ-C 30 studies with small sample sizes 
comparing data generated from the baseline group and reference groups or the general population. 
In addition, the amount of data published was collected at different time ranges making it difficult 
to generalize our findings. A meta-analysis was not feasible given the heterogeneity across selected 
articles.  
 
8.2 Discussion of the Results  
The aim of this study was to compare quality of life (QoL) of cancer survivors treated with 
cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) versus 
current oncological standard care. 
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This section will discuss the nursing strategy appropriate to improve quality of life after 
cytoreductive surgery combined with hypothermic intraperitoneal chemotherapy. In this review, 
nursing care strategies were developed from the self-care theory following the CRS-HIPEC 
experience outlined in the QLQ-C30 literature with a phenomenological approach that brings 
evidence to improve care delivery from baseline through long-term follow-up. 
Living with illness such as cancer and receiving chemotherapy certainly impede meeting self-care 
requisites. This is indicated by the increased readmission after discharge. Understanding patients’ 
perspectives from preoperative decision making to postoperative recovery process, is relevant in 
addressing gaps with regard to the delivery of healthcare, and improvement of patient outcomes 
(Francescutti et al., 2019).The oncology nurse has key roles in the entire care pathway to inform, 
coordinate, support, and follow-up and facilitate the patients’ interaction with healthcare team 
(Hasanpour-Dehkordi, 2016), and participation in decision-making (Thaysen et al., 2019). 
The diagnosis label of self-care deficit indicates an impaired ability to perform or complete certain 
activity of daily living (Chang, Uman & Hirsch, 1998). Patients experience CRS+HIPEC treatment 
as a turning point generating uncertainties (Eriksson et al., 2014). They often complain about getting 
inadequate discharge information for patients to manage and self-monitor their symptoms once at 
home (Kang, Gillespie, Tobiano &Chaboyer, 2020). Failure to provide adequate information about 
the treatment pathway to people with peritoneal metastases was a factor to increased feeling of 
worries about the disease recurrence in cancer survivors (Leo Swenne et al., 2017).  
Following treatment, patients with peritoneal metastases experience difficulties to return to work 
within a period of time varying from three months to several months. Dealing with rapid changes 
along with financial constraints may be not easy to cope with. Initially, individuals struggle coping 
with the consequences of illness on their own. However, it is not clear to know to what extent 
healthcare systems will support patients once readmitted due to postoperative complications (Leo 
Swenne et al., 2017).  
All studies in the baseline group showed a high QoL before surgery except patients requiring the 
secondary CRS-HIPEC treatment (Zeng et al., 2017). Findings portraying a decrease in QoL scores 
three-six months after surgery and a return to baseline during 12-24 months after surgery are 
consistent with other studies performed with different QoL measurement tools (Hinkle et al., 2017; 
Glockzin, Schlitt & Piso, 2009; Dodson, 2016; Passot, 2014). In clinical practice, QoL may be a 
predictor of treatment effect signifying that the baseline assessment of the QoL before treatment may 
have a prognostic value (Fayers & Machin, 2016, p 16). In order to improve survival, the baseline 
assessment per se can probably help to select appropriate candidates for CRS+HIPEC treatment.  
In CRS-HIPEC survivors, pain, fatigue, insomnia, nausea/vomiting and diarrhea are more prevalent 
and may improve below the baseline level in a period of 48 months after surgery (Schmidt et al., 
2005; Hamilton et al., 2016; Liu et al., 2016). However, patients have to live with long-term 
symptoms on a daily basis (Schmidt et al., 2005). The effectiveness of symptom management 
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depends on attempts to understand the interdependent relationships between symptom experience, 
symptom management, and symptom outcomes from the patient’s perspective (Larson et al., 1994).  
Symptoms commonly experienced by CRS-HIPEC recipients are not dissimilar from symptoms 
recognized to be associated with the cancer disease process. Two groups of symptoms cluster 
believed to affect the QoL were: a psycho-neurological cluster (pain, fatigue, insomnia and cognitive 
disturbance) and gastrointestinal cluster (nausea, vomiting and diarrhea, constipation) (Barsevick, 
2016). However, the resultant of poor QoL is not necessarily related to a number of symptom 
clusters, only one serious symptom such as pain may be enough to reduce the overall QoL (Fayers 
& Machin, 2016). 
 
Self-care has been used as a tool to control symptoms in cancer survivors. Various symptoms 
experienced by patients undergoing chemotherapy persisted particularly nausea, vomiting, tiredness 
and weakness (Rhodes, Watson & Hanson, 1988). Supportive care is invaluable, but the resultant 
symptom management often weighs on the responsibility of the individual patients (Dodd, Janson, 
Facione & Faucett, 2001). A nurse-led self-care education has been tested successfully to improve 
QoL in females with breast cancer (Shahsavari, Matory, Zare, Taleghani & Kaji, 2015).  
Traditionally, functional factors, symptoms and global health constitute the main elements of the 
QoL that are evaluated prior to and after CRS-HIPEC treatment. However, some clinical factors  
such as the presence of stoma, length of surgery and disease recurrence have been reported to affect 
the QoL of selected patients (Passot, Bakrin, Roux, Vaudoyer, Gilly, Glehen & Cotte, 2014). These 
factors should be considered as part of QoL assessment after CRS-HIPEC. Further studies may be 
recommended to assess more factors associated with QoL after CRS-HIPEC treatment. The 
persistence of diarrhea and constipation 6-36 months (Schmidt et al., 2005; Lim et al., 2010; Alves 
et al., 2010; Tsilimparis et al., 2013; Albertsmeier et al., 2014; Chia et al., 2016; Stearns et al., 2018) 
may be explained by either side effect of chemotherapy or that they are opioid -induced. The 
incidence of post-treatment constipation and diarrhea among cancer survivors had been estimated to 
persist up to 10 years after the cessation of treatment with great impact on their QoL (Mcquade, 
Stojanovska, Abalo, Bornstein & Nurgali, 2016; Bloechl-Daum, Deuson, Mavros, Hansen & 
Herrstedt, 2006).  
The holistic aspect of self-care experience that has been raised in one study among cancer survivors 
includes physical, social and psychological aspects where a patient-nurse partnership is needed 
(Lindquist, Enblom & Bergmark, 2015). Hanucharurnkui, & Vinya-Nguag (1991) showed that 
patients who participate in self-care, experience less pain and fewer postoperative complications than 
avoiding self-care. In general, self-care behavior improves all aspects of the QoL and the mental 
component of health in particular (Weng, Dai, Huang & Chiang, 2010).  
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Current estimate indicates three- and five-years disease-free survival at 50 % and 25 % respectively 
following the initial diagnosis in patients who underwent complete cytoreductive surgery combined 
with HIPEC (Burnett et al., 2019). However, gaps in delivery of cancer care services occur between 
different phases of treatment including palliative care. Every phase requires support and assistance 
to overcome healthcare system barriers. Oncology nurse navigators provide information about what 
to do when treatment ends, coping strategies, and specific practical information. A way to ease 
patient feeling abandoned and vulnerable at the end of active treatment is to facilitate linkage to 
health care resources (Pedersen & Hack, 2011). 
Following CRS+HIPEC treatment, cancer recurrence is a risk factor associated with poor QoL in 
selected patients. Recurrence was detected early in a period of 6-12 months in 30-70% of which 
24 % of patients underwent surgery with a curative intent (Braam, Van Oudheusden, De Hingh, 
Nienhuijs, Boerma, Wiezer & Van Ramshorst, 2014; Hinkle, Botta, Sharpe, Dickson, Deneve & 
Munene, 2017). A recent study shows that over the course of the year, 38% of CRS+HIPEC patients 
were referred to palliative care to improve their QoL (Morris, Gani, Hammad, Peltier, Gamblin, 
Turaga, & Johnston, 2017). However, the QoL becomes redefined in palliative care with possible 
improvement at a new level of meaning through symptom control and psychological support as the 
continuum of care (Ferris et al., 2009). 
The emotional functioning, which was lower at the baseline rapidly improved at three months 
postoperatively, remained above the baseline during recovery (Dodson, 2016). Improvement on 
emotional well-being can be explained according to Hinkle et al. (2017) by preoperative desperation 
of the diagnosis followed by postoperative hope after a successful operation. Recovery was slower 
in cognitive and gastrointestinal functions with persistent fatigue and insomnia. A return to the 
baseline level could take more than 24 months (Jess et al., 2008; Tsilimparis et al., 2013; Stearns et 
al., 2018). Better scores than the baseline values were reported after 12 months in the social and 
functional role (Alves et al., 2010). Cognitive impairment was reported in both baseline groups (Jess 
et al., 2008; Lim et al., 2010; Alves et al., 2010; Tsilimparis et al., 2013; Stearns et al., 2018) and in 
the general population group (Schmidt et al., 2005) while it was similar in the different reference 
groups (Zenasni et al., 2009; Hamilton et al., 2016; Liu et al., 2016; Düzgün et al., 2018). A 
significant cognitive impairment may persist longer than seven years after surgery (Stearns et al., 
2018).  
The global QoL scores after CRS-HIPEC was lower than the QoL of the general population (Schmidt 
et al., 2005; Stearns et al., 2018). However, the QoL of CRS-HIPEC recipients was similar to the 
QoL of cancer patients undergoing classic surgical intervention with or without major complication 
(Zenasni et al., 2009 Tan et al., 2013; Hamilton et al., 2016; Liu et al., 2016; Düzgün et al., 2018). 
Similar results have been found in patients who underwent curative resection of colorectal primary 
tumor at 12 months after surgery (Zhu, Hanna, Boutros & Alexander, 2013).   
Postoperative complications which require reoperation and cancer recurrence are facets associated 
with readmission after discharge and delaying recovery after CRS/HIPEC (Martin et al., 2016; 
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Hinkle et al., 2017; Chia, Tan, Lim, Soo & Teo, 2016). The way these factors affected the QoL of 
the CRS-HIPEC recipients as reported in QLQ-C30 studies was not fully understood (Chia et al., 
2016; Hamilton et al., 2016).  
Postoperative self-care activities may be performed by an individual to promote quality of life and 
well-being for a return to functional activities impaired after surgery. Although relative increase in 
QoL to better functioning activity level has been observed after 3-month CRS-HIPEC treatment 
(Piso et al., 2009), the QoL in long-term survivors remained significantly below the baseline level 
(Huo, Richards, Liauw & Morris, 2015). It is important to realize that the individual recovery state, 
life experience, socio-cultural factors and available resources may affect these activities (Masters, 
2015, p.156). 
The CRS+HIPEC is an expensive procedure since patients have to pay a special fee for this 
treatment. Recipients have reported financial instabilities both short-term and long-term in 
comparison with the reference population (Schmidt et al; 2005; Stearns et al., 2018). Despite being 
around for decades, the cost of CRS-HIPEC treatment cannot be paid by all candidates. For example, 
the hospital costs for this treatment in 2013 were estimated at 37000 US dollars excluding drug and 
expenses for an average hospital stay of 21 days in Sweden (Ludwigs, 2013). This amount which 
differs in areas without state-funded medical care (Stearns et al., 2018) may be difficult to refund 
during a recovery time. The financial impact on selection criteria to be qualified for CRS+HIPEC 
treatment may be raised as an ethical issue. 
Cultural variations or differences weigh on how patients receive, assimilate, and deal with health-
related issues. Cancer patient’s experience can demonstrate such similarities and differences from 
the predominant culture in which the health care facility is located (Payne, 2012, p.36). This leads 
to the important goal of delivering a culturally competent nursing care as described through 
Madeleine Leininger’s (2002) theory of transcultural nursing. 
Cancer survivors need a continuum care that spans an entire lifetime to ensure continuity of care 
across the hospital, home and other settings (Shulman et al., 2009). There is growing evidence 
showing that nurses help patients to cope with short-and long-term effects of cancer diagnosis and 
therapy along with management of comorbid conditions. Partnership with the patient and the family 
caregiver while encouraging behaviors that lead to health promotion is essential in all aspects of care 
to reduce the continuum deficit (Morgan, 2009).   
This is the first study to review QLQ-C30 studies linking data generated from baseline and from 
control groups or the general population after CRS+HIPEC. The QoL which was lower than in the 
general population though similar as compared with reference groups suggests that the CRS-HIPEC 
treatment does not affect the QoL of recipients differently from other major cancer treatment 
procedures. The return to the pre-diagnosis QoL may be not reached in a period less than 3-4 years 
after treatment. This should be related to the 30 % risk of recurrence within 12 months and 





Recipients of CRS-HIPEC commonly experience symptoms independently reported to predict 
changes in short-term and long-term QoL. Except the emotional dimension which recovers rapidly 
above the baseline, the overall short-term QoL is characterized by impairment of all dimensions and 
an increase in symptom scores in the first three months after CRS-HIPEC treatment. The long-term 
QoL may return to the baseline or reference group level 12 months after CRS-HIPEC treatment. 
However, fatigue, pain, insomnia, and diarrhea symptoms may persist along with cognitive 
impairment. The QoL trend for patients undergoing CRS-HIPEC is characterized by high scores at 
baseline, a short-term decrease in 1-3 months postoperatively, an increase 6-12 months followed by 
improvement in long-term survivors or a decrease as a result of recurrence. The CRS-HIPEC 
recipients need a continuum of care across the hospital, home and community to ensure that patients 
not only live longer but also have a better QoL. Cancer survivors require ongoing health care that 
supports the patient and family’s self-care in order to deal with the progressive symptoms and cancer 
recurrence. 
Although CRS-HIPEC treatment has been there for more than two decades, quality of life of 
survivors is still affected by lack of information about the treatment pathway pertaining to the 
procedure itself, discharge, rehabilitation, and complications. To improve quality of life, findings 
suggest a comprehensive approach of care that will consider delivery of adequate information, 
individuals’ preferences, perceptions, and participation in decision-making. The oncology nurse has 
a myriad of roles to play in the entire care pathway, mostly informative, coordinating, supportive, 
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Topic Covered Searching and Abstracts Quality the Results
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Search 
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(2005) 
 x x x  
Jess et al. (2008)    x  
Zenasni et al. 
(2009 
   x  
Lim et al. (2010)    x  
Alves et al. 
(2010) 
    x 
Tan et al. (2013)  x x x  
Tsilimparis et al. 
(2013) 
 x  x  
Chia et al. (2014)  x x x  
Albertsmeier et 
al. (2014) 
 x x x  
Chia et al. (2016)  x x x  
Hamilton et al. 
(2016) 
   x  
Liu et al. (2016)   x   
Zeng et al. 
(2017) 
    x 
Duzgun et al. 
(2018) 
  x x  
Stearns et al. 
(2018) 
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Quality Assessment of Selected Articles
Assessment
Author Aim/Research Problem Methods/Design Main Outcomes Scores
(year)
1. Schmidt et al. (2005) To analyze postoperative morbidity Analyse patient data The global health status was lower than 30
and mortality. compiled into a database the reference population. Leading symptoms
To assess QoL QLQ-C30 questionnaire were fatigue, insomnia and pain
n=20
2. Jess et al. (2008) To assess the QoL QLQ-C30 questionnaire After 24 months, physical function, fatigue and 32
n=23 pain remained under the baseline level.
Cognitive function declined.
3. Zenasni et al. (2009) To evaluate impact of HIPEC QLQ-C30 questionnaire QoL is good in 65.4% of participants 32
on the QoL n=68, all recurrence excluded Functional scale was satisfactory.
4. Lim et al. (2010). To assess QoL at least 12 months QLQ-C30 questionnaire QoL scores decreased in 60 % of patients 
after HIPEC n=32 in the early postoperative assessment(1 month) 34
Return to baseline at 3 months in 53.3%.
Overall QoL recoved in 73 % at 12 months 
after HIPEC
5. Alves et al. (2010) To assess health related QoL after QLQ-C30 questionnaire Significant improvement in emotional well-being, 30
CRS-HIPEC n=49 appetite and global QoL after 1 year following
surgery
6. Tan et al. (2013) To assess QoL outcomes after QLQ-C30 questionnaire Global health status, functional scale and symptom 34
CRS-HIPEC in an Asian cancer center n=27 scores were largery similar between patients 
Reference group: Disease-free after CRS-HIPEC and the control group.
cancer patients Cognitive functioning and fatigue scores were better
in the CRS-HIPEC group.
7.Tsilimparis et al. (2013) To investigate health-related QoL QLQ-C30 questionnaire Physical and role function improved at 6 month and 
over time in after CRS-HIPEC n=90 were close to baseline at 24-month assessment. 32
treatment Emotional function recovered to baseline by month 12.
Cognitive and social function had slow recovery.
Fatigue , diarrhea , dyspnea and sleep disturbance 
persisted at 6-month assessment but improved later.
8. Chia et al. (2014) QoL after CRS-HIPEC QLQ-C30 questionnaire Better scores at 6 months after CRS-HIPEC followed 34
Factors to improve QoL n=63 by a decline period and an improvment period after 
2 years.














9.Albertsmeier et al. (2014) To evaluate QoL after QLQ-C30 questionnaire Global health status was not impaired significantly.
CRS-HIPEC prospectively n=33 Functional scales deteriorated 3 months after surgery 32
(physical, role, and social). Fatigue, pain, dyspnea, 
insomnia and diarrhea increased but returned to 
baseline within 9 months.
10.Chia et al.(2016) Prospective QoL after QLQ-C30 questionnaire Physical and role functioning scores declined at 
CRS-HIPEC and attempt n=23 3 months but returned to baseline at 6 months. 33
to identify factors affecting Emotional and social functioning scores increased
QoL between 6-12 months. Improvement in all symptoms 
scores at 6-12 months was reported.
Factors affecting QoL:  High PCI score, longer duration
of surgery, the presence of stoma and recurrence.
11. Hamilton et al.(2016) Impact of major complications QLQ-C30 questionnaire At 6 months, the global health score was 68.1%, while 
on patient's QoL after CRS-HIPEC n=42 the worse-rated sypmtom scores reported were 
Assessment after 6 months diarrhea (39.8%) and fatigue (35.4%). There were no 31
CRS-HIPEC significant differences in 6-month QoL scores between
patients with and without major complications 
in any specific domains.
12.Liu et al. (2016) Survival  after CRS morbidity QLQ-C30 questionnaire Patients receiving CRS-HIPEC have similar QoL 30
and mortality n=30 as other patients 6 months postoperatively
Evaluation 6 months
postoperatively
13. Zeng et al. (2017) To evaluate the QoL before and QLQ-C30 questionnaire Secondary CRS-HIPEC improved QoLof patients. 34
after secondary CRS-HIPEC n=50 Symptoms were reduced .
14. Düzgün et al. (2018)       To investigate short-term QLQ-C30 questionnaire Functional scale and symptom scores were the same 30
QoL after CRS-HIPEC 6 months after surgery between CRS-HIPEC and cancer patients operated 
n=42 without CRS-HIPEC.
15. Stearns et al. (2018) Long-Term QoL after CSR-HIPEC QLQ-C30 questionnaire Patients' physical, role and social function scores 
which was not repoted in previous n=86 were impaired until 12 months after HIPEC.
studies The symptom scores ( fatigue, appetite loss, insomnia, 34
and financial difficulties) worsened significantly 
in the first 12-months but normalized after. 
Cognitive function impairement persisted beyond
12 months parallell with constipation and diarrhea.
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1. Schmidt, U., Dahlke,M.H., Klempnauer,J., 




Emotional Lower than the reference group
Functional Scale





Dyspnea 24.80% reported QoL alteration
Symptoms Insomnia 38.1% reported QoL alteration
Appetite loss Insignificant
Constipation 21.6% of the sample
Diarrhea 26.5% of the sample




Long-term Lower than the reference population
Notes: No baseline but the reference group which is the general Norwegian population, n=20 
Assessment in long-term survivors with 4 years as the mean average age.








2. Jess, P. H., Iversen, L. B., Nielsen, M. C., 
Hansen, F., Laurberg, S., & Rasmussen, P. (2008). 
Denmark
Physical Lower than baseline after 12 months
Role Improved after 6 months
Emotional Above baseline already at 3 months postoperatively
Functional Scale
Cognitive Declined at 24 months
Social Improved after 6 months, returned to baseline after 12 months
Fatigue Increased at 3,6, and 24 months
Nausea/vomiting Return to baseline after 24 months
Pain Decline at 3,6 and 12 months
Dyspnea Increased at 24 months
Symptoms Insomnia Declined a little
Appetite loss Under baseline scores at 12 months
Constipation Insignificant
Diarrhea Insignificant
Financial Increased in comparison to baseline
Difficulties
Short-term Significant decrease in the immediate postoperative period.
Global Health
Long-term Return to baseline level after 24 months
Baseline QoL , the patient was followed prospectively in a clinic at 3,6,12,18, and  24 months
Notes: after CRS+HIPEC, n=23




3. Zenasni,F., Botella,M., Elias,D., Dauchy,S., 
Boige,V., Malka,D., …Pocard, M. (2009)
France
No QoL alteration Reported alteration
Physical 95.7% 4.3%
Role 89.9% 10.1%







Symptoms Insomnia 71.0% 29.0%








QoL long-term survivors(≥1 year after CRS-HIPEC without recurrence)
Notes: No French baseline QoL norm studies to compare the QLQ-C30 scores.





4. Lim,C., Tordjmann,D., Gornet,J.M.,
Nemeth,J., Valleur,P., Pocard,M. (2010)
France
Physical Decreased significantly in the few months after CRS-HIPEC
in 47%
Role
Emotional 1/3 of patients reported emotional problems including depression
Functional Scale
Cognitive Decline after 1 month, little improvement after 3 months but did not
reach the baseline after 1 year CRS-HIPEC treatment
Social Decreased in 53,4%
Fatigue In 1/5 of patients
Nausea/vomiting At baseline  level after 12 months
Pain Increased significantly postoperatively, persisted in 26 %
of patients after 3 months CRS-HIPEC
Dyspnea Reported in 15% 
Symptoms Insomnia 26% of patients affected
Appetite loss 1/3 of patients affected, and persisted in 15% after 3 months 
Constipation Persistance in 21 % after 1 year of treatment
Diarrhea Persistance in 21 % after 1 year of treatment
Financial
Difficulties 16 % affected after 1 yeat treatment
Short-term QoL score had decreased in 60 % of patients
Global Health Return to baseline in 53% of patients after 3 months 
Long-term 55% recovered their QoL at 6 months, and 73 % at 12 months
Psychological problems, diarrhea and constipation were reported
in 20% of survivors over the course of the first year after CRS-HIPEC
Notes: QoL at baseline, at 1, 3, 6, and 12 months
The first QoL after CRS-HIPEC study in France, n=32
Decline of QoL reported in 60% after 1 month associated with postoperative morbidity (35%),and ADL difficulties in 47%. QoL improved after 3 m n hs, was restaure  in 50  
QoL was recovered to the preoperative level or higher after 1 year in 73%









5. Alves, Mohamed, Yadegarfar, Youssef, & Moran. (2010). 
UK
Physical Return to baseline after 12 months
Role Decline after 3 months, improved above baseline at 12 months
Emotional Improved after 3 months
Functional Scale
Cognitive Return to baseline after 12 months
Social Above baseline after 1 year
Fatigue Decline at 3 months, baseline at 6 months, improved at 12 months
Nausea/vomiting Worse at 1 month, improved at 3 and 12 months, return to baseline
at 6 months.
Pain Improved at 3 months, deteriorated at 6 months but improved
beyond baseline at 12 months.
Dyspnea Lower than baseline in 12 months after CRS-HIPEC
Symptoms Insomnia Improved after 3 months
Appetite loss Improved after 3 months
Constipation Improved after 1 month
Diarrhea Increased after 3, 6 and 12  months
Financial Not assessed
Difficulties
Short-term At baseline lever after 3 months
Global Health
Long-term Above baseline at 6 and 12 months




6. Tan, W. J., Wong, J. F. S., Chia, C. S., 
Tan, G. H. C., Soo, K. C., & Teo, M. C. C. (2013). 
Singapore











Symptoms Insomnia 84% 16%







Long-term 67% which was almost similar to a reference group.








7. Tsilimparis, N., Bockelmann, C., Raue, W., Menenakos, C., 
Perez, S., Rau, B., & Hartmann, J. (2013). 
Germany
Physical Close to baseline at 24-month measurement
36-month survivors had better physical function than at baseline
Role Recovery was prolonged, close to baseline at 24-month measurement
Emotional Lower than baseline level 12 moths after surgery
Cognitive Slow recovery to baseline by month 12
Functional Scale
Social Required 36 months to recover to baseline level.
Fatigue Persistent at 6-month follow-up, improved later at 24-36 months
Nausea/vomiting Improved at 6 months, but worsened again over the time
Pain Close to baseline at 6-month
Dyspnea Persistent at 6-month follow-up, improved later at 24-36 months
Insomnia Persistent at 6-month follow-up
Symptoms Appetite loss Close to baseline at 6-month follow up, improved later.
Constipation Close to baseline at 6-month
Diarrhea Persistent at 6-month follow-up, improved later at 24-36 months
Financial Unspecified
Difficulties
Short-term A significant decrease in all elements of QoL
Global Health
Long-term Close to baseline 24 months postoperatively








8. Chia, C. S., Tan, W. J., Wong, J. F. S., Tan, G. H. C., 
Lim, C., Wang, W., . . . Teo, M. C. C. (2014). 
Singapore
No QoL alteration Reported alteration
Physical 86.80% 13.20%
Role 84.70% 15.3%













Short-term Improved in a period ≥ 6 months
Global Health
Long-term 68.80% Decrease below baseline in a period between 6-24 months,
improved later after 24 months
Notes: No baseline scores but a comparison group








9. Albertsmeier, M., Hauer, A., Niess, H., Werner, J., 
Graeb, C., & Angele, M. (2014). 
Germany
Physical Return to baseline values within 9 months
Role Return to baseline values within 9 months
Emotional Not altered significantly
Functional Scale
Cognitive Not altered significantly
Social Return to baseline values within 9 months
Fatigue Return to baseline values within 9 months
Nausea/vomiting Not severe. No significant differences with baseline
Pain Return to baseline values within 9 months
Dyspnea Return to baseline values within 9 months
Symptoms Insomnia Return to baseline values within 9 months
Appetite loss Lower than preoperative values after 9 months
Constipation Increased above baseline after 9 months
Diarrhea Return to baseline after 18 months
Financial Not improved 
Difficulties
Short-term QoL reduced 3 months postoperatively
Global Health
Long-term Not impaired significantly. Returned to the preoperative level
around 18months. Some patients viewed their health status
that recovered better than baseline.






10. Chia, C., Tan, G., Lim, C., Soo, K., & Teo, M. (2016). 
Singapore
Physical Decline  at 3 months, return to baseline at 6 months 
Role Decline  at 3 months, return to baseline at 6 months
Functional Scale Emotional Improvement at 6-12 months
Cognitive
Social Improvement at 6-12 months
Fatigue Improvement at 6-12 months
Nausea/vomiting Improvement at 6-12 months
Pain Improvement at 6-12 months
Dyspnea Improvement at 6-12 months
Symptoms Insomnia Improvement at 6-12 months
Appetite loss Improvement at 6-12 months
Constipation Improvement at 6-12 months
Diarrhea Improvement at 6-12 months
Financial Improvement at 6-12 months
Difficulties
Short-term Decline 3 months postoperative
Global Health
Long-term Improved 6-12 months
Notes: QoL baseline and at 3,6, and 12 months postoperatively
n=23
Improved in all symptom scalesat 6-12 months.
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11. Hamilton, T., Taylor, D., Cannell, E., McCart, L., & Govindarajan, A. (2016). 
Canada





















No preoperative QoL assessment. QoL evaluation after 6 months CRS-HIPEC.
Notes: The purpose was to investigate if there was significant differences between
patients with and without major complications. The results showed that 






























Notes: QoL evaluation 6 monts after operation, n=30 in each group
QoL was similar in both groups except N/V and insomnia



















Symptoms Insomnia 35.23% 31.55%








Notes: Comparison of baseline QoL scores before and after secondary CRS-HIPEC, n=50
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14. Düzgün, Ö., Sarıcı, İ. Ş., & Gökçay, S. (2018). 
Turkey
CRS+HIPEC Oncology patients




















Global Health Long-term 65% 68%
No baseline comparison. QLQ-C30 questionnare was used after 6 months CRS-HIPEC.
Notes:       No baseline comparison. QlQ-C30 questionnaire was used at 6 months after CRS-HIPECQoL comparis n  between CRS-HIPEC patie ts and oncology patie s operated without





15. Stearns, A., Malcomson, T., Punnett, L., Abudeeb, G., 
Aziz, H., Selvasekar, O., . . . O’Dwyer, E. (2018).
UK Physical
Impaired 12 months postoperatively
Role
Impaired 12 months postoperatively
Emotional
Impaired significantly
Functional Scale Cognitive Impairement persisted 12 months before return to the reference 
population norms.
Social
Impaired 12 months after surgery
Fatigue








Symptoms Worsened in the first 12 months, and then normalized
Appetite loss
Worsened in the first 12 months, and then normalized
Constipation
Increase, normalized after 12 months 
Diarrhea
Pesisted to 36 months postoperatively
Financial




Did not differ from the reference population group.
QoL at 3,6,9,12,18,24,36,48, and 60 months, n=86
Notes: Baseline and a reference group were used to compare QoL
High functional scale scores and low syptom scores mean good QoL.
54 
Appendix E 
EORTC QLQ-C30 (version 3) Questionnaire 
We are interested in some things about you and your health. Please answer all of the questions 
yourself by circling the number that best applies to you. There are no “right” or “wrong” answers. 
The information that you provide will remain strictly confidential 
 
© Copyright 1995 EORTC Study Group on Quality of Life. Version 3.0. 
For permission to use contact: EORTC Quality of Life Department, Ave. E. Mounier 83, B.11, 
1200 Brussels, Belgium (http//groups.eortc.be/gool) 
 
Your birthdate (Day, Month, Year):       …./…./…./…./…./…./…./…./
Today's date (Day,Month, Year):       31…./…./…./…./…./…./…./…./
Not at All A Little Quite a BitVery Much
1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase? 1 2 3 4
2. Do you have any trouble taking a long  walk? 1 2 3 4
3. Do You have any trouble taking  a short walk outside of the house ? 1 2 3 4
4. Do you need to stay in bed or a chair during the day ? 1 2 3 4
5. Do You need help with eating , dressing , washing yourself or using the toilet? 1 2 3 4
During the past week Not at All A Little Quite a BitVery Much
6. Were you limited in doing either your work or other daily activities? 1 2 3 4
7.Were you limited in pursuing your hobbies or other leisure time activities? 1 2 3 4
8. Were you short of breath? 1 2 3 4
9. Have you had pain? 1 2 3 4
10.Did  you need to rest ? 1 2 3 4
11.Have you had trouble sleeping? 1 2 3 4
12. Have you felt weak? 1 2 3 4
13. Have you lacked  appetite? 1 2 3 4
14. Have you felt nauseated? 1 2 3 4
15. Have you vomited? 1 2 3 4
16. Have you been constipated? 1 2 3 4
17. Have you had diarrhea? 1 2 3 4
18. Were you tired? 1 2 3 4
19. Did pain interfere with your daily activities 1 2 3 4
20. Have you had difficulty in concentrating on things, like reading a newspaper or watching television? 1 2 3 4
21. Did you feel tense? 1 2 3 4
22. Did you worry? 1 2 3 4
23. Did you feel irritable? 1 2 3 4
24. Did you feel depressed? 1 2 3 4
25.Have you had difficulty remembering  things? 1 2 3 4
26. Has your physical condition or medical treatment interfered with your family life? 1 2 3 4
27. Has your physical condition or medical treatment interfered with your social activities? 1 2 3 4
28. Has your physical condition or medical treatment caused your financial difficulties? 1 2 3 4
For the following questions please circle the number between 1 and 7 that best applieas to you
29. How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Very poor Excellent
